Kolon TissueGene, Inc.
950160.KQ
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.36T
Close$
$-5431.49
135.1% downside
Current Fair Value
135.1% downsideOvervalued by 135.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.36 Trillion |
|---|---|
| Enterprise Value | $1.35 Trillion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2361.76 |
| Beta | 0.41 |
| Outstanding Shares | 84,807,230 |
Return
| Return on Equity | -88.49% |
|---|---|
| Return on Assets | -35.20% |
| Return on Invested Capital | -57.94% |
Valuation & Multiples
| P/E Ratio | -7.31 |
|---|---|
| PEG | 3.9 |
| Price to Sales | 276.07 |
| Price to Book Ratio | 6.39 |
| Enterprise Value to Revenue | 284.39 |
| Enterprise Value to EBIT | -11.17 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 0.31 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Kolon TissueGene, Inc.
58 employees
CEO: Moon J. Noh Kolon TissueGene, Inc. is a biopharmaceutical firm specializing in the advancement of clinical-stage cell-based treatments for osteoarthritis. Its flagship offering is TG-C, a proprietary platform technology that integrates allogeneic pr...